Publicaciones científicas
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
Bronte G(1), Rolfo C(2), Passiglia F(1), Rizzo S(1), Gil-Bazo I(3), Fiorentino E(4), Cajozzo M(5), Van Meerbeeck JP(6), Lequaglie C(7), Santini D(8), Pauwels P(9), Russo A(1).
BACKGROUND:
Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.
MATERIALS AND METHODS:
Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities.
RESULTS:
Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883-5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203-2.525) in favor of platinum-based doublets. G3-4 hematological toxicities were also more frequent in this group.
CONCLUSION:
This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
CITA DEL ARTÍCULO Crit Rev Oncol Hematol. 2015 Apr 11. pii: S1040-8428(15)00066-9. doi: 10.1016/j.critrevonc.2015.03.010.